Biogen Agreement Further Validates Anavex Life Sciences (AVXL) AV2-73 - FBR
- The FTC Confirms Antitrust Charges Against Qualcomm (QCOM) for Monopolizing Semiconductor Device Used in Cell Phones
- US Drone Market Could Reach 6 Million By 2019 - Oppenheimer
- Eli Lilly (LLY) to Acquire CoLucid Pharmaceuticals (CLCD) for $960M
- United Airlines (UAL) Tops Q4 EPS by 5c
- Obama shortens sentence of Manning, who gave secrets to WikiLeaks
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
FBR Capital analyst Christopher James weighed in on Anavex Life Sciences (NASDAQ: AVXL) after the company announced that it has signed a material transfer agreement with Biogen under which Biogen will test AV2-73 in a validated preclinical CNS assay. As a reminder, AV2-73 is a sigma-1 receptor antagonist with potential to promote recovery of motor function and reactivation of neuroplasticity in patients suffering from neurocognitive diseases.
James commented, "We believe these early studies could lead to its advancement into other neurodegenerative and demyelination diseases such as Parkinson's disease and multiple sclerosis. We view this agreement with BIIB as additional validation for AV2-73's potential in multiple CNS-related disorders, but remain focused on the development plan for the Phase II study with AV2-73 in Rett syndrome, an orphan disease with no approved therapies."
The firm maintained an Outperform rating and price target of $10.00
Shares of Anavex Life Sciences closed at $3.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Weight Watchers (WTW) Climbs to Session High, Gaining 9%
- Stocks with Implied Volatility Movement
- Buy Neurocrine Bio. (NBIX) on Any Pullback Following Adult Tourette's Data - Piper Jaffray
Create E-mail Alert Related CategoriesAnalyst Comments, FDA, Momentum Movers, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!